AI isn’t replacing the workflow — it’s joining it. The real opportunity in applying AI to early-stage R&D isn’t about uprooting how science is done, but embedding intelligence into the messiness of how it already works.

We've mapped out 5 key layers where digital pharma services are unlocking real value—from R&D to medical affairs.

Valink Therapeutics is redefining how we target diseases with their LiliumX(™) robotic drug screening platform.

By using advanced AI and multi-omics data, MultiOmic Health is discovering new biomarkers and treatment targets for complex metabolic conditions.

Using bacteriophages that precisely target harmful bacteria without touching the good ones.

Bacteriophages (or just "phages") are an interesting area of science. Naturally occurring viruses that only attack bacteria, they were discovered at the turn of the century but generally lost in the noise of antibiotic development.